球體培養無需支架，通過貼壁細胞趨向于聚集的特性形成細胞球體，可觀察腫瘤的發生，維持腫瘤體基本特征，是用于 3D 細胞培養的最常見、最通用的無支架方法之一，常用的球體包括胚胎小體、乳腺球、腫瘤球體、肝細胞球和神經球，用于CSC研究。此款培養基不含血清，由干細胞生長重組蛋白，維生素，礦物質等組成，添加小分子化合物AMP,BMP inhibitor，Rock及SMOC-2 等抑制雜細胞生長并促進腫瘤干細胞以及惡性細胞株成球。

培養基優勢：

1. 大部分腫瘤細胞株可直接使用TSCM成球

2.可培養復雜的球體和類器官

3.可維持同質腫瘤球的傳代和擴增

4.無血清無直接動物源蛋白組分，可保持實驗的統一性和可驗證性。

培養基配方：

基礎培養基：250ml (P2400) ，細胞生長因子（TSGCS）25ml (P2402)，G/A：2.5ml(SD0038）

備注：100ml瓶裝無套件，為整瓶配制。

說明：產品僅科研使用。

1. A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes.  Cancer Immunol Immunother 72, 1673–1683 (2023). 

https://doi.org/10.1007/s00262-022-03355-6

2. The ameliorative effect on chemotherapy-induced injury and tumor immunosuppressive microenvironment of the polysaccharide from the rhizome of Menispermum dauricum DC

https://doi.org/10.1016/j.ijbiomac.2024.131828

3. Xiaoli Wang, Yan Zhou, Xiaomin Lu, Lili Shao；Machine learning models reveal ARHGAP11A's impact on lymph node metastasis and stemness in NSCLC published: 31 October 2024 

https://doi.org/10.1002/biof.2141

4. Lei Shi，Jian Huang，Xifeng Fei，Bao He，Zhixiang Sun，guan sun，DMC-BH derivative DMC-GF inhibits the growth of glioma stem cells by targeting the TRIM33/SLC25A1/mitochondrial oxidative phosphorylation pathway

https://www.researchsquare.com/article/rs-5306321/v1

5. J. et al. DMC-BH derivative DMC-GF inhibits the growth of glioma stem cells by targeting the TRIM33/SLC25A1/mitochondrial oxidative phosphorylation pathway. J Transl Med 23, 363 (2025)

https://doi.org/10.1186/s12967-025-06355-z

6. Licoisoflavone A inhibits colorectal cancer cell proliferation through targeting CDK2-Cyclin E1 axis-mediated cell cycle transition

https://doi.org/10.1016/j.bcp.2025.117124

7. Chitosan/NH2-MIL-125 (Ti) scaffold loaded with doxorubicin for postoperative bone tumor clearance and osteogenesis: An in vitro study

https://doi.org/10.1016/j.ijbiomac.2024.130368

8. Targeting HNRNPA2B1 to overcome chemotherapy resistance in gastric cancer stem cells: Mechanisms and therapeutic potential

https://doi.org/10.1016/j.jbc.2025.108234

9. Xie, H., Lu, L., Wang, S. et al. Deciphering the crucial role of IGF2BP3 in modulating stemness traits of salivary adenoid cystic carcinoma. Med Oncol 42, 513 (2025). 

https://doi.org/10.1007/s12032-025-03068-7

10. The role of glutamine/Nrf2-enhanced PHGDH in Cadmium-induced lactate utilization

https://doi.org/10.1016/j.freeradbiomed.2025.12.015

11. Knockdown of CCT2 inhibits the malignant progression of hepatocellular carcinoma cells by impairing STAT3 activation，Published online on: February 25, 2026

https://doi.org/10.3892/or.2026.9086

12. Xu, Z., Li, Z., Deng, Z. et al. TOLLIP targets GSDME-NT-carrying endocytic vesicles for autophagy to regulate pyroptosis and chemotherapy efficacy. Nat Cell Biol (2026)

https://doi.org/10.1038/s41556-026-01902-2

13.ST6Gal1 influences the esophageal squamous cell carcinoma resistance to IFN-γ by regulating the expression of IFN-γ receptor 1,

https://doi.org/10.1016/j.bbagen.2026.130941